Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome August 26, 2020 Source Science Translational Medicine
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression July 9, 2020 Source Nature Communications
Substantial improvements in overall seizure burden and seizure-free days in patients with Dravet syndrome treated with zorevunersen: Results from Phase 1/2a and open‑label extension studies September 1, 2025 Source IEC 2025
EMPEROR Phase 3 study design: Evaluation of zorevunersen as a potential disease-modifying therapy for Dravet syndrome September 1, 2025 Source IEC 2025
Zorevunersen demonstrates potential as a disease-modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning with up to 36 months of maintenance dosing in open-label extension studies August 31, 2025 Source IEC 2025
Zorevunersen demonstrates potential as a disease-modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning with up to 24 months of maintenance dosing in open-label extension studies July 10, 2025 Source EPNS 2025
Zorevunersen (STK-001) demonstrates potential for disease modification, including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome December 6, 2024 Source AES 2024
Patients with Dravet syndrome in open-label extension studies of zorevunersen (STK-001) have durable reductions in seizure frequency and ongoing improvements in cognition and behavior December 6, 2024 Source AES 2024
Small changes on the Vineland-3 are meaningful to caregivers of patients with Dravet syndrome December 6, 2024 Source AES 2024
Spectral EEG analysis demonstrates decreased slow-wave activity in patients with Dravet syndrome after treatment with zorevunersen (STK-001), an antisense oligonucleotide December 6, 2024 Source AES 2024
24-Month Analysis of BUTTERFLY A Prospective, Observational Study to Investigate Seizures and Comorbidities in Children and Adolescents with Dravet Syndrome September 10, 2024 Source EEC 2024